Indumathy Varadarajan MD
Hematologic Oncology
Immune Effector Cell Program Medical Director (UVA) and Asst. Professor of Hematology/ Oncology (UVA)
Join to View Full Profile
1240 Lee StCharlottesville, VA 22908
Phone+1 434-982-3209
Fax+1 434-244-7434
Dr. Varadarajan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Drexel University College of Medicine/Hahnemann University HospitalFellowship, Hematology and Medical Oncology, 2014 - 2017
Mount Auburn HospitalResidency, Internal Medicine, 2011 - 2014
Sri Ramachandra Medical CollegeClass of 2009
Certifications & Licensure
VA State Medical License 2018 - 2026
PA State Medical License 2014 - 2017
MA State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT Start of enrollment: 2021 Feb 19
Publications & Presentations
PubMed
- Purpura Fulminans fromin an Immunocompromised Host.Indumathy Varadarajan, Natalie Pham, Karen Ballen
Case Reports in Oncology. 2024-10-29 - 5 citationsThe impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma.Kiarash Salafian, Christine Mazimba, Leonid Volodin, Indumathy Varadarajan, Asal Pilehvari
Bone Marrow Transplantation. 2024-04-01 - 7 citationsSurvivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.Ciara L Freeman, Reginald Atkins, Indumathy Varadarajan, Meghan Menges, Jeffrey Edelman
Clinical Cancer Research. 2023-11-14
Press Mentions
When Chemo Failed, CAR T-cell Therapy Took Away a Father’s CancerSeptember 22nd, 2022- UVA Cancer Center’s Cutting-Edge Immunotherapy Soon Available With No Hospital StayJuly 6th, 2023
- Supercharged Immune Cells: UVA to Offer Outpatient Cutting-Edge Cancer TreatmentJuly 6th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
